TickerFacts.

Nexentis Technologies Inc. (NXTS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$4.16M
Year ended 2025-12-31
2018-12-31: -$443.1K2019-12-31: -$1.90M2020-12-31: -$1.30M2021-12-31: -$4.65M2024-12-31: -$3.27M2025-12-31: -$4.16M-$4.16M
2018-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$4.16Mn/m2026-03-31, From 2025-01-01
2024-12-31-$3.27Mn/c2026-03-31, From 2024-01-01
No annual figure between 2021-12-31 and 2024-12-31.
2021-12-31-$4.65Mn/m2023-03-27, From 2021-01-01
2020-12-31-$1.30Mn/m2022-03-31, From 2020-01-01
2019-12-31-$1.90Mn/m2021-03-29, From 2019-01-01
2018-12-31-$443.1Kn/a2020-03-30, From 2018-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31-$4.16Mn/m
Jyong Biotech Ltd. (MENS)2025-12-31-$2.51Mn/m
Galectin Therapeutics Inc (GALT)2024-12-31-$42.43Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$270.0Kn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31-$9.22Mn/m
Lftd Partners Inc. (LIFD)2025-12-31$1.47Mn/m
Moleculin Biotech, Inc. (MBRX)2025-12-31-$25.01Mn/m
Lite Strategy, Inc. (LITS)2025-06-30-$17.09Mn/m
Allarity Therapeutics, Inc. (ALLR)2024-12-31-$27.23Mn/m

Compare NXTS, MENS, GALT, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗